Tensive, a biotech scaleup that develops innovative solutions to give female breast cancer survivors a natural breast reconstruction and breast augmentation patients a superior clinical and aesthetic outcome, announces that it has closed a EUR 14 million Series A financing led by Panakès Partners and with the participation of the EIC Fund, together with other institutional investors and business angels. In conjunction with this investment, Sanjay Kakkar joined the company as CEO.
“We are delighted to welcome Panakès as a lead investor along with EIC, CDP, Recomec and other investors, and appreciate the confidence they have shown in our vision and capabilities. The addition of Sanjay Kakkar to the team is an important step forward, as he brings with him a wealth of experience in developing life sciences companies, which will be instrumental in propelling Tensive towards its goals,” says Alberto Cantaluppi, chief medical officer and co-founder, in a note.
“We are thrilled to lead this Series A funding round for Tensive, whose innovation and vision are transforming the landscape of women’s health. Its innovative technology has the power to make a profound difference in the lives of breast cancer survivors around the world. It is a real privilege to support solutions that create a lasting and meaningful impact for patients while offering the potential for significant financial returns for investors. We look forward to working closely with the Tensive team as we embark on this journey of development, growth and global expansion,’ says Diana Saraceni, founder and managing partner of Panakès Partners.
“This funding round is a key milestone in realising the potential of Tensive’s innovative technology. The funds from the Series A round will allow the company to complete a pivotal clinical study to evaluate the safety and performance of the company’s lead product, Regenera, in patients undergoing reconstructive surgery after lumpectomy for malignant breast lesions,” adds Alessandro Tocchio, chief strategy officer and co-founder. The company recently announced the launch of the pivotal study on Regenera, involving leading breast surgery centres in Italy and Spain.
“This capital injection and valuable addition to the management team bring important resources and expertise that will be critical to Tensive’s growth. This vote of confidence from our current and new investors is critical as we continue to work towards our mission of improving the quality of life for breast cancer survivors by restoring their natural breasts,” says Valentina Morigi, chief financial officer and co-founder.
Sanjay Kakkar, is a biotech and medtech entrepreneur with 30 years of experience in multinational, early-stage and high-growth companies. He has a proven track record in building innovative life science companies in Europe, Asia and the US and in promoting new technologies for improving human health. Prior to joining Tensive, he served as CEO at Tranquis of which he is still chairman, Peptilogics, Armetheon and Trigen of which he was also co-founder, and was founder and chairman of Jai Medica. Before becoming a serial entrepreneur in the life sciences industry, he held research and development positions at Pharmacia, now Pfizer, and Novartis. Sanjay holds a medical degree from King’s College, University of London, a master’s degree in healthcare management from Harvard University and a master’s degree in preventive cardiology from Imperial College. Sanjay was born and raised in the UK and has worked in the UK, Italy, Germany, India and the US.
‘Regenera’s unique properties hold incredible promise for the creation of a new class of bioabsorbable implants that could offer a practical, effective and easy-to-use option for managing breast pathology after lumpectomy, ultimately providing a natural breast shape and feel in a single step, with a minimally invasive and potentially cost-effective procedure,’ says the new CEO. I am really excited to be working closely with a group of pioneering innovators and leading investors to harness this powerful technology and provide breast cancer survivors and healthcare professionals with an important new medical device to address a huge unmet clinical need’. (photo by Victoria Strukovskaya on Unsplash)
ALL RIGHTS RESERVED ©